PALO ALTO, Calif., Feb. 15 /PRNewswire/ -- Frost & Sullivan selected Aethlon Medical, Inc. as the recipient of the 2006 Technology Innovation Award in the field of biodefense technologies for homeland security. This Award acknowledges the company's development of the inventive Hemopurifier(TM) technology, which can be deployed as the first line of defense against a broad spectrum of drug- and vaccine-resistant pathogens.
Each year, this Award is presented to a company that has carried out new research that has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognizes the quality and depth of a company's research and development program as well as the vision and risk taking that enabled it to undertake such an endeavor.
There has been a huge lapse in the development of effective drug or vaccine countermeasures for diseases caused due to biological warfare and emerging pandemic issues. Currently, many biotechnology companies are working on identifying methods to innovate technologies to deliver solutions that address this urgent requirement, and at the forefront of this trend is Aethlon Medical.
Aethlon Medical has established its competence in developing viral filtration technologies that can clear drug- and vaccine-resistant pathogens from blood circulation. The technology can also be deployed against currently untreatable pathogens released through bioterrorism.
"This technology can filter diverse pathogens including Smallpox, Ebola, Marburg and Anthrax toxins, and is based on the fundamental principles of affinity chromatography and hemodialysis that enable the identification, isolation and removal of the viruses prior to cell/organ infection," says Frost & Sullivan research analyst Haritha Ramachandran. "The technology can also identify and eliminate genetically modified envelope viruses and can be targeted for use against chronic conditions such as HIV and Hepatitis-C."
The Hemopurifier(TM) is based on a two-stage process to reduce toxins in the body. The first stage involves the separation of viruses and viral toxins from blood using established techniques, similar to those employed in blood dialysis. The second part involves the immobilization of affinity agents that bind tightly to glycoproteins that reside on the envelope of viruses.
The Hemopurifier(TM) concept may be the only technology that effectively rids a virus from the blood/medium where it has been detected. Due to this unique feature, the Hemopurifier appears best positioned to treat patients when conventional drugs or vaccines are not effective or are not readily available.
"With several key patents already filed and several more pending, Aethlon Medical has successfully established a robust research and development program," notes Haritha. "Through productive R&D effort, promising products and strategic alliances, Aethlon Medical is poised to leave an indelible mark in the field."
About Aethlon Medical, Inc.
Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at http://www.aethlonmedical.com .
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .
Contact: Stacie Jones 210.247.2450 Stacie.jones@frost.com
Frost & SullivanCONTACT: Stacie Jones of Frost & Sullivan, +1-210-247-2450, orStacie.jones@frost.com
